Wenhua Jiang

Title: Innovations of Wenhua Jiang in Biopharmaceuticals

Introduction

Wenhua Jiang is a notable inventor based in Beijing, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of drug targets for the treatment of epithelial tumors. His innovative work has the potential to impact cancer diagnosis and therapy.

Latest Patents

Wenhua Jiang holds a patent for an IgG epitope and its applications as a drug target. The patent describes the C1 domain of non-B cell-derived IgG, which features an N-glycosylated sialic acid modification at the Asn162 site. The functionality of this antigen is dependent on the sialylation of the site. The invention outlines the use of the IgG epitope as a drug target for preparing drugs aimed at diagnosing and treating epithelial tumors. Furthermore, it highlights the role of sialyltransferase ST3GAL4 as a potential drug target for tumor therapeutic drugs. The research also indicates that integrin β4 is co-expressed and co-localized with IgG containing the epitope, suggesting that IgG can serve as a marker for auxiliary detection of epithelial tumors.

Career Highlights

Wenhua Jiang is associated with Beijing Sig Biopharmaceutical Technology Co., Ltd., where he continues to advance his research and innovations in the biopharmaceutical sector. His work is characterized by a strong focus on the molecular mechanisms underlying tumor biology and therapeutic interventions.

Collaborations

Wenhua Jiang collaborates with notable colleagues, including Xiaoyan Qiu and Jingshu Tang. Their combined expertise contributes to the advancement of research in the field of biopharmaceuticals.

Conclusion

Wenhua Jiang's innovative contributions to the development of drug targets for epithelial tumors exemplify the potential of biopharmaceutical research. His work not only enhances our understanding of tumor biology but also paves the way for new therapeutic strategies.